Demands of cancer care in Europe continue to increase significantly, with the number of incident cancer cases in Europe projected to increase by 14.1% by 2030. This leads to a growing demand for innovative cancer treatments among patients, payers, physicians, and society. At the same time, the understanding of the complex biology of cancer is growing, and as a result, pharmaceutical companies are developing a multitude of new therapeutic agents.
This trend for new, effective therapies creates more treatment options for patients. However, it confronts physicians with an increasingly expanding number of potential therapeutic options, which each need to be understood and adopted effectively. To become familiar with the huge volume of available information, physicians need to learn continuously about medical guideline changes and marketed treatments. In conclusion, future decision-making processes will become ever-more complex, with the potential outcome of sub-optimal or even incorrect treatment choices being made. Furthermore, some patients have disease characteristics for which evidence of guideline recommendations is scarce and physicians lack information about real-world treatment outcomes. Hence, the challenges to be addressed are assisted guideline-based decision-making and the discovery of knowledge about treatment outcomes in real-world settings. As the latter challenge requires analysis of large data sets, the application of Artificial Intelligence (AI) will be a key technology.
The scope of this call topic is to establish guideline-based decision support and platform solutions to generate knowledge discovery for breast, lung and prostate cancer with applicability to other indications, in several European (EU member states and H2020 associated countries) ‘model’ regions. The funded action will focus only on breast, lung and prostate cancer. These indications show a high number of cases per year, a high, unmet medical need, multiple available therapeutic options and a fast-evolving treatment environment. Expansion to other indications is not part of the funded action but a proposed solution should allow for expansion afterwards. The three core objectives of this call topic are as follows:
Objective 1: Establish a guideline-based decision support for prioritised indications
Objective 2: Establish a structured and interoperable data platform to unlock real-world-data potential in an oncology network
Objective 3: Leverage the real-world-data gathered by the action to establish an AI-knowledge base and support treatment decisions for prioritized indications.
Date limite : 29 septembre 2020
From a legal point of view, most IMI2 projects must have a minimum of 3 partners based in 3 different EU Member States or countries associated to the Horizon 2020 programme. The exact rules for each Call for proposals are set out in the Call documents and you should read these carefully. In practice, in order to carry out the work required to achieve the project objectives, most projects will require more than 3 partners. The exact number will depend very much on the size and scope of the project. The important thing is to demonstrate that your consortium contains all the expertise required to deliver what is expected of it, as set out in the Call documents, while avoiding unnecessary redundancy between partners.